Ticker LaunchDirect listing · LABT
Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc. (LABT) went public through a direct listing on Nasdaq Capital Market on Apr 23, 2026, with a reference price of $10.00. Lucosky Brookman advised the company.
Lakewood-Amedex Biotherapeutics Inc. is a biotechnology company developing treatments for infectious diseases, including antibiotic-resistant bacterial strains such as MRSA and VRE, to address the growing threat of antimicrobial resistance.
- Status
- Direct listing
- Ticker
- LABT
- Exchange
- Nasdaq Capital Market
- Listed
- Apr 23, 2026
- Price
- $10.00
- First filed
- Jan 9, 2026
- Company counsel
- Lucosky Brookman
- Sector
- Biotech & pharma
- Country / state
- FL
More on this listing for subscribers
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Jan 9, 2026
- Latest amendment Apr 6, 2026
- Final prospectus (424B4) Apr 23, 2026
- All filings on EDGAR CIK 2079272
Other Biotech & pharma direct listings in 2026
- Polaryx Therapeutics, Inc.PLYX · Feb 2, 2026